Neuroleptic malignant syndrome due to risperidone treatment in a child with joubert syndrome

Journal of the National Medical Association

Volumn 101, Issue 3, 2009, Pages 273-275

  Vurucu, Sebahattin ^a   Congologlu, Ayhan ^a   Altun, Demet ^a   Unay, Bu Lent ^a   Akin, Ridvan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Central nervous system disorders; Drugs; Neurology

Indexed keywords

BIPERIDEN; CLONAZEPAM; PARACETAMOL; RISPERIDONE;

ADD ON THERAPY; ADOLESCENT; AGITATION; APRAXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAPHORESIS; DRUG WITHDRAWAL; DYSPHAGIA; DYSTONIA; EYE MOVEMENT DISORDER; FEVER; HUMAN; INSOMNIA; JOUBERT SYNDROME; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SWEATING;

ABNORMALITIES, MULTIPLE; ACETAMINOPHEN; ADOLESCENT; ANALGESICS, NON-NARCOTIC; ANTIPSYCHOTIC AGENTS; BIPERIDEN; CRYOTHERAPY; DOPAMINE ANTAGONISTS; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NEUROLEPTIC MALIGNANT SYNDROME; RISPERIDONE; SEROTONIN ANTAGONISTS;

EID: 64549120306     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30858-0     Document Type: Article

References (10)

1. Dahlstrom JE, Cookman J, Jain S. Joubert syndrome: an affected female with bilateral colobomafa. Pathology. 2000:32:283-285.
2. Ananth J, Aduri K, Parameswaran S, et al. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiat-rica. 2004;16:219-228
3. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185-202.
4. Viejo LF, Morales V, Puñal P, et al. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta PsychiatrScand. 2003:107:45-49.
5. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiafr Serv. 1998:49:1163-1172.
6. Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry. 2002:159:149-150.
7. Abu-Kishk I, Toledano M, Reis A, et al. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol. 2004;42:921-925.
8. Mills KC. Serotonin syndrome: a clinical update. Crit Care Clin. 1997;13:763-783.
9. Mihara K, Kondo T, Suzuki A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet. 2003:117:57-60.
10. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999; 156:169-180. ?